Citations

Showing 10 of 108135 citations.

Regulatory T Cell Therapy of Graft-versus-Host Disease: Advances and Challenges
Bolivar-Wagers, Sara , Blazar, Bruce R. , Blazar, Bruce R , Hefazi, Mehrdad

Mayo Clinic

International Journal of Molecular Sciences | September 7, 2021 | Volume: 22 | Issue: 18 | Pages: 9676

10.3390/ijms22189676 | PMID 34575843 Get It

Graft-versus-host disease (GVHD) is the leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Immunomodulation using regulatory T cells (Tregs) offers an exciting option to prevent and/or treat GVHD as these cells naturally function to maintain immune homeostasis, can induce tolerance following HSCT, and have a tissue reparative function. Studies to date have established a clinical safety profile for polyclonal Tregs. Functional enhancement through genetic engineering offers the possibility of improved potency, specificity, and persistence. In this review, we provide the most up to date preclinical and clinical data on Treg cell therapy with a particular focus on GVHD. We discuss the different Treg subtypes and highlight the pharmacological and genetic approaches under investigation to enhance the application of Tregs in allo-HSCT. Lastly, we discuss the remaining challenges for optimal clinical translation and provide insights as to future directions of the field.
Novel Strategies for Nanoparticle-Based Radiosensitization in Glioblastoma
Ramírez-Loera, Cristopher , Malouff, Timothy D. , Seneviratne, Danushka S. , Palmer, Joshua D. , Ramirez-Loera, Cristopher , Palmer, Joshua D , Ruiz-García, Henry , Trifiletti, Daniel M.

Mayo Clinic

International Journal of Molecular Sciences | September 7, 2021 | Volume: 22 | Issue: 18 | Pages: 9673

10.3390/ijms22189673 | PMID 34575840 Get It

Radiotherapy (RT) is one of the cornerstones in the current treatment paradigm for glioblastoma (GBM). However, little has changed in the management of GBM since the establishment of the current protocol in 2005, and the prognosis remains grim. Radioresistance is one of the hallmarks for treatment failure, and different therapeutic strategies are aimed at overcoming it. Among these strategies, nanomedicine has advantages over conventional tumor therapeutics, including improvements in drug delivery and enhanced antitumor properties. Radiosensitizing strategies using nanoparticles (NP) are actively under study and hold promise to improve the treatment response. We aim to describe the basis of nanomedicine for GBM treatment, current evidence in radiosensitization efforts using nanoparticles, and novel strategies, such as preoperative radiation, that could be synergized with nanoradiosensitizers.
A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer
Yadav, Siddhartha , Leone, José Pablo , Leon‐Ferre, Roberto A. , Ruddy, Kathryn J. , Yadav, Siddhartha , Giridhar, Karthik V.

Mayo Clinic

Breast Cancer Management | September 7, 2021 | Volume: 10 | Issue: 3 | Pages: No page available

10.2217/bmt-2021-0001 Get It

Development of Gastroenterology and Transplant Hepatology Milestones 2.0: A Guide For Programs, Faculty, and Fellows
Shah, Brijen J. , Onken, Jane E., Jou, Janice H. , Obstein, Keith L. , Pardi, Darrell S. , Richter, Seth, Rose, Suzanne , Szyjkowski, Ronald, Fix, Oren K. , Fix, Oren K , Edgar, Laura , Reddy, Gautham

Mayo Clinic

Hepatology | September 7, 2021 | Volume: 74 | Issue: 4 | Pages: 2226-2232

10.1002/hep.32097 | PMID 34491583 Get It

Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells
Moku, Gopikrishna , Vangala, Swathi, Yakati, Venu , Gali, Chaitanya Chakravarthi , Vyas, Amber , Saha, Soumen , Madamsetty, Vijay Sagar

Mayo Clinic

Anti-Cancer Agents in Medicinal Chemistry | September 7, 2021 | Volume: 22 | Issue: 5 | Pages: 914-925

10.2174/1871520621666210901102425 | PMID 34488592 Get It

Background: Histone deacetylases (HDACs) are the enzymes that catalyze the removal of the acetyl group from lysine residues and regulate several biological processes. Suberoylanilide hydroxamic acid (SAHA) is a notable HDAC inhibitor that exhibited remarkable anti-proliferative efficiency by alleviating gene regulation against solid and hematologic cancers. Aim: The aim of this study was to develop new chemotherapeutic agents for breast cancer treatment, therefore, a novel series of Suberoylanilide hydroxamic acid (SAHA) analogs were investigated as anticancer agents. Methods: We designed and synthesized a novel series of analogs derived from SAHA by substituting alkyl, alkoxy, halo, and benzyl groups at different positions of the phenyl ring. The newly synthesized analogs were assessed for their cytotoxic potential against four human cancer cell lines in comparison with healthy cell lines, using several biological assays Results: SAHA analogs displayed significant cytotoxic potential with IC50 values ranging from 1.6 to 19.2 μM in various tumor cell lines. Among these analogs, 2d (containing 3-chloro, 4-floro substitutions on phenyl moiety), 2h (containing 3,4-di chloro substitutions on phenyl moiety), and 2j (containing 4-chloro, 3-methyl substitutions on phenyl moiety) showed significant cytotoxic potential with IC50 values ranging from 1.6 to 1.8 μM in MCF-7 (breast carcinoma) cell line. More importantly, these analogs were found to be non-toxic towards healthy primary human hepatocytes (PHH) and mouse fibroblast cells (NIH3T3), which represent their tumor selectivity. These analogs were further analyzed for their effect on cell migration, BrdU incorporation, Annexin V-FITC and cell cycle arrest (Sub-G1 phase). Remarkably, analogs 2d, 2h, and 2j displayed significant HDAC inhibition than the parent SAHA molecule. Further studies also confirmed that these SAHA analogs are efficient in inducing apoptosis, as they regulated the expression of several proteins involved in mitochondrial or intrinsic apoptosis pathways. Findings in the Chick Chorioallantoic Membrane (CAM) assay studies revealed anti-angiogenic properties of the currently described SAHA analogs Conclusion: From anti-proliferative study results, it is clearly evident that 3,4-substitution at the SAHA phenyl ring improves the anti-proliferative activity of SAHA. Based on these findings, we presume that the synthesized novel SAHA analogs could be potential therapeutic agents in treating breast cancer.
Initiation of Gender-Affirming Testosterone Therapy in a Lactating Transgender Man
Oberhelman, Sara S. , Chang, Alice Y. , González, César A. , Braith, Andrew, Lteif, Aida, Oberhelman, Sara , Chang, Alice, Gonzalez, Cesar, Gonzalez, Cesar , Singh, Ravinder J.

Mayo Clinic

Journal of Human Lactation | September 7, 2021 | Volume: 38 | Issue: 2 | Pages: 339-343

10.1177/08903344211037646 | PMID 34490813 Get It

Introduction: Transgender and gender diverse individuals may choose to provide their infants with human milk. Lactating transgender men may experience gender dysphoria and desire to initiate or reinitiate gender-affirming testosterone therapy. However, there is limited safety data regarding use of testosterone during lactation. Main Issue: A 30-year-old G2P2 transgender man with gender dysphoria sought to initiate gender-affirming testosterone therapy while lactating. Management: Subcutaneous testosterone was self-administered beginning at 13 months post-partum. We prospectively collected data on circulating testosterone concentrations in parent serum, milk, and infant serum over 5 months until the infant self-weaned. The infant was monitored for growth and development at routine pediatric outpatient appointments. Parent serum testosterone concentrations rose with the initiation of testosterone therapy, reaching therapeutic concentrations by Day 14. Milk testosterone concentrations also increased with a maximum concentration of 35.9 ng/dl when the lactating parent was on a dose of 80 mg subcutaneous testosterone cypionate weekly. The calculated milk/plasma ratio remained under 1.0 and the calculated relative infant dose remained under 1%. The infant had no observable side effects, and his serum testosterone concentrations remained undetectable throughout the study period. Conclusion: This is the first study with data regarding human milk and infant serum testosterone concentrations during the initiation of gender-affirming testosterone therapy in a lactating individual. This evidence can help families and clinicians with decisions regarding lactation and testosterone use.
First, Do No Harm: Understanding Primary Care Providers’ Perception of Risks Associated With Discussing Weight With Pediatric Patients
Loth, Katie A. , Lebow, Jocelyn , Uy, Marc James Abrigo , Ngaw, Samantha M., Neumark‐Sztainer, Dianne , Berge, Jerica M. , Lebow, Jocelyn , Neumark-Sztainer, Dianne

Mayo Clinic

Global Pediatric Health | September 7, 2021 | Volume: 8 | Issue: No issue available | Pages: No page available

10.1177/2333794x211040979 | PMID 34514059 Get It

Many health care providers struggle with if- and how-to discuss weight with their pediatric patients. This study used one-on-one interviews with primary care providers (n = 20) to better understand their: (1) perception of risks associated with talking about weight with pediatric patients, (2) commitment to adhering to best practices of pediatric weight management, and (3) approaches to mitigate perceived risks. Providers felt concerned that discussing weight with children during clinic visits may have unintended negative impacts. Despite perceived risks, providers continued regular BMI screening and weight-focused conversations, but took care with regard to language and approach with the goal of mitigating perceived risks. Findings suggest that pediatric primary care providers perceive that engaging in weight-related discussions with their patients has the potential to lead to negative, unintended consequences. Future research is needed to understand if weight-focused conversations should be avoided altogether or if there are approaches that can effectively mitigate risks.
Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project
Eastell, Richard , Vittinghoff, Eric , Lui, Li‐Yung, Pávó, Imre , Chines, Arkadi , Khosla, Sundeep , Cauley, Jane A. , Mitlak, Bruce , Bauer, Douglas C. , Bouxsein, Mary , Black, Dennis M. , Khosla, Sundeep , Cauley, Jane A , Mitlak, Bruce , Bauer, Douglas C , Bouxsein, Mary L , Black, Dennis M , Vittinghoff, Eric , McCulloch, Charles E.

Mayo Clinic

Journal of Bone and Mineral Research | September 7, 2021 | Volume: 37 | Issue: 1 | Pages: 29-35

10.1002/jbmr.4433 | PMID 34490915 Get It

ABSTRACT The surrogate threshold effect (STE) is defined as the minimum treatment effect on a surrogate that is reliably predictive of a treatment effect on the clinical outcome. It provides a framework for implementing a clinical trial with a surrogate endpoint. The aim of this study was to update our previous analysis by validating the STE for change in total hip (TH) BMD as a surrogate for fracture risk reduction; the novelty of this study was this validation. To do so, we used individual patient data from 61,415 participants in 16 RCTs that evaluated bisphosphonates (nine trials), selective estrogen receptor modulators (four trials), denosumab (one trial), odanacatib (one trial), and teriparatide (one trial) to estimate trial-specific treatment effects on TH BMD and all, vertebral, hip, and nonvertebral fractures. We then conducted a random effects meta-regression of the log relative fracture risk reduction against 24-month change in TH BMD, and computed the STE as the intersection of the upper 95% prediction limit of this regression with the line of no fracture reduction. We validated the STE by checking whether the number of fractures in each trial provided 80% power and determining what proportion of trials with BMD changes ≥ STE reported significant reductions in fracture risk. We applied this analysis to (i) the trials on which we estimated the STE; and (ii) trials on which we did not estimate the STE. We found that the STEs for all, vertebral, hip, and nonvertebral fractures were 1.83%, 1.42%, 3.18%, and 2.13%, respectively. Among trials used to estimate STE, 27 of 28 were adequately powered, showed BMD effects exceeding the STE, and showed significant reductions in fracture risk. Among the validation set of 11 trials, 10 met these criteria. Thus STE differs by fracture type and has been validated in trials not used to develop the approach. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Hallmarks of RET and Co-occuring Genomic Alterations inRET-aberrant Cancers
Adashek, Jacob J. , Desai, Aakash , Andreev-Drakhlin, Alexander , Roszik, Jason , Cote, Gilbert J. , Subbiah, Vivek , Desai, Aakash P , Subbiah, Vivek

Mayo Clinic

Molecular Cancer Therapeutics | September 7, 2021 | Volume: 20 | Issue: 10 | Pages: 1769-1776

10.1158/1535-7163.mct-21-0329 | PMID 34493590 Get It

AbstractActivating receptor-tyrosine kinase rearranged during transfection (RET) mutations and fusions are potent drivers of oncogenesis. The recent FDA approvals of highly potent and selective RET inhibitors, selpercatinib and pralsetinib, has altered the therapeutic management of RET aberrant tumors. There is ample evidence of the role of RET signaling in certain cancers. RET aberrations as fusions or mutations occur in multiple cancers, however, there is considerable phenotypic diversity. There is emerging data on the lack of responsiveness of immunotherapy in RET-altered cancers. Herein, we review the registrational data from the selective RET-inhibitor trials, and comprehensively explore RET alterations in pan-cancer adult malignancies and their co-alterations. These co-occuring alterations may define the future of RET inhibition from specific selective targeting to customized combination therapies as data are rapidly emerging on both on-target and off-target acquired resistance mechanisms. Fascinatingly, oncogenic RET fusions have been reported to mediate resistance to EGFR inhibition and KRASG12C inhibition.
The impact of nonoperative hip and core injuries on National Football League athlete performance
Jildeh, Toufic R. , Castle, Joshua , Buckley, Patrick J. , Nowak, C, Okoroha, Kelechi R. , Buckley, Patrick , Tramer, Joseph S.

Mayo Clinic

The Physician and Sportsmedicine | September 7, 2021 | Volume: 51 | Issue: 1 | Pages: 27-32

10.1080/00913847.2021.1976603 | PMID 34488522 Get It